Persistent expression of canine factor IX in hemophilia B canines

Gene Therapy

Volumn 6, Issue 10, 1999, Pages 1695-1704

  Chao, H ^a   Samulski, R J ^a   Bellinger, D A ^a   Monahan, P E ^a   Nichols, T C ^a   Walsh, C E ^a  

^a UNIVERSITY OF NORTH CAROLINA SCHOOL OF MEDICINE   (United States)

Author keywords

Canine; Gene therapy; Hemophilia B; Muscle; Parvovirus

Indexed keywords

ANTIBODY; BLOOD CLOTTING FACTOR 9; COMPLEMENTARY DNA; MESSENGER RNA; NEUTRALIZING ANTIBODY; VIRUS DNA;

ADENO ASSOCIATED VIRUS; ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BLEEDING; BLOOD CLOTTING TIME; CONTROLLED STUDY; DOG; EPISOME; GENE THERAPY; HEMOPHILIA B; INTRAMUSCULAR DRUG ADMINISTRATION; NONHUMAN; PARTIAL THROMBOPLASTIN TIME; PARVOVIRUS; PLASMA TRANSFUSION; PRIORITY JOURNAL; PROTEIN EXPRESSION; SKELETAL MUSCLE; TRANSGENE; VIRUS CAPSID;

ANIMALS; ANTIBODIES, VIRAL; BLOOD COAGULATION; BLOTTING, SOUTHERN; DEPENDOVIRUS; DNA; DOG DISEASES; DOGS; FACTOR IX; GENE EXPRESSION; GENE THERAPY; GENE TRANSFER TECHNIQUES; GENETIC VECTORS; HEMOPHILIA B; HUMANS; INJECTIONS, INTRAMUSCULAR; MUSCLE, SKELETAL; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; RNA, MESSENGER; TIME FACTORS;

EID: 0032862984     PISSN: 09697128     EISSN: None     Source Type: Journal    
DOI: 10.1038/sj.gt.3301024     Document Type: Article

References (49)

1. Lusher J, Transfusion therapy in congenital coagulopathies. Hematol Oncol Clin N Am 1994; 8: 1167-1180.
2. Brinkhous K et al. Recombinant human factor IX: replacement therapy, prophylaxis, and pharmacokinetics in canine hemophilia B. Blood 1996; 88: 2603-2610.
3. Soucie J et al. Hepatitis A virus infections associated with clotting factor concentrate in the United States. Transfusion 1998; 38: 573-579.
4. National Hemophilia Foundation. The treatment of hemophilia and related bleeding disorders, Medical Advisory No. 312. In: Medical and Scientific Advisory Council (MASAC) Recommendations. New York, 1998, p 11-34.
5. Lofqvist T, Nilsson I, Berntorp E, Pettersson H. Haemophilia prophylaxis in young patients - a long-term follow-up. J Intern Med 1997; 241: 395-400.
6. Petrini P, Lindvall N, Egberg N, Blomback M. Prophylaxis with factor concentrates in preventing hemophilic arthropathy. Am J Pediat Hematol Oncol 1991; 13: 280-287.
7. Kay M et al. In vivo gene therapy of hemophilia B: sustained partial correction in factor IX-deficient. Science 1993; 262: 117-119.
8. Dai Y et al. Cellular and humoral immune responses to adenoviral vectors containing factor IX gene: tolerization of factor IX and vector antigens allows for long-term expression. Prof Nat Acad Sci USA 1995; 92: 1401-1405.
9. Rabinowitz J, Samulski J. Adeno-associated virus expression system for gene transfer. Curr Opin Biotechnol 1998; 9: 470-475.
10. Berns K, Bohenzky R. Adeno-associated viruses: an update. Adv Virus Res 1987; 32: 243-306.
11. Afione S et al. In vivo model of adeno-associated virus vector persistence and rescue. J Virol 1996; 70: 3235-3241.
12. Flotte T et al. Stable in vivo expression of the cystic fibrosis transmembrane conductance regulator with an adeno-associated virus vector. Proc Natl Acad Sci USA 1993; 90: 10613-10617.
13. Xiao X, Li J, Samulski R. Efficient long-term gene transfer into muscle tissue of immunocompetent mice by adeno-associated virus vector. J Virol 1996; 70: 8098-8108.
14. Flotte T, Carter B. Adeno-associated virus vectors for gene therapy. Gene Therapy 1995; 2: 357-362.
15. Dong J, Fan P, Frizzell R. Quantitative analysis of the packaging capacity of recombinant adeno-associated virus. Hum Gene Ther 1996; 7: 2101-2112.
16. Clark K, Sferra T, Johnson P. Recombinant adeno-associated viral vectors mediate long-term transgene expression in muscle. Hum Gene Ther 1997; 8: 659-669.
17. Yao S, Kurachi K. Expression of human factor IX in mice after injection of genetically modified myoblasts. Proc Natl Acad Sci USA 1992; 89: 3357-3361.
18. Herzog R et al. Stable gene transfer and expression of human blood coagulation factor IX after intramuscular injection of recombinant adeno-associated virus. Proc Nat Acad Sci USA 1997; 94: 5804-5809.
19. Evans J et al. Canine hemophilia B resulting from a point mutation with unusual consequences. Proc Nat Acad Sci USA 1989; 86: 10095-10099.
20. Liles D et al. Extravascular administration of factor IX: potential for replacement therapy of canine and human hemophilia B. Thromb Haemostas 1997; 77: 944-948.
21. Monahan P et al. Direct intramuscular injection with recombinant AAV vectors results in sustained expression in a dog model of hemophilia. Gene Therapy 1998; 5: 40-49.
22. Kurachi S, Hitomi Y, Furukawa M, Kurachi K. Role of intron I in expression of the human factor IX gene. J Biol Chem 1995; 270: 5276-5281.
23. Xiao X, Li J, Samulski R. Production of high-titer recombinant adeno-associated virus vectors in the absence of helper adenovirus. J Virol 1998; 72: 2224-2232.
24. Evans J et al. Molecular cloning of a cDNA encoding canine factor IX. Blood 1989; 74: 207-212.
25. Anderson L, Human parvoviruses. J Infect Dis 1990; 161: 603-608.
26. Ferrari F, Samulski T, Shenk T, Samulski R. Second-strand synthesis is a rate-limiting step for efficient transduction by recombinant adeno-associated virus vectors. J Virol 1996; 70: 3227-3234.
27. Flannery J et al. Efficient photoreceptor-targeted gene expression in vivo by recombinant adeno-associated virus. Proc Natl Acad Sci USA 1997; 94: 6916-6921.
28. Nilsson I, Berntorp E, Lofqvist T, Pettersson H. Twenty-five years' experience of prophylactic treatment in severe haemophilia A and B. J Intern Med 1992; 232: 25.
29. Herzog R et al. Long-term correction of canine hemophilia B by gene transfer of blood coagulation factor IX mediated by adeno-associated viral vector. Nature Med 1999; 5: 56-63.
30. Snyder R et al. Correction of hemophilia B in canine and murine models using recombinant adeno-associated viral vectors. Nature Med 1999; 5: 64-70.
31. Snyder R et al. Persistent and therapeutic concentrations of human factor IX in mice after hepatic gene transfer of recombinant AAV vectors. Nat Genet 1997; 16: 270-276.
32. Summerford C, Samulski R. Membrane-associated heparan sulfate proteoglycan is a receptor for adeno-associated virus type 2 virions. J Virol 1998; 72: 1438-1445.
33. Summerford C, Bartlett J, Samulski R. AlphaVbeta5 integrin: a co-receptor for adeno-associated virus type 2 infection. Nature Med 1999; 5: 78-82.
34. Qing K et al. Human fibroblast growth factor receptor 1 is a co-receptor for infection by adeno-associated virus 2. Nature Med 1999; 5: 71-77.
35. Summerford C, Samulski R. Viral receptors and vector purification: new approaches for generating clinical-grade reagents. Nature Med 1999; 5: 587.
36. Chiorini J et al. Cloning of adeno-associated virus type 4 (AAV4) and generation of recombinant AAV4 particles. J Virol 1997; 71: 6823-6833.
37. Kessler P et al. Gene delivery to skeletal muscle results in sustained expression and systemic delivery of a therapeutic protein. Proc Natl Acad Sci USA 1996; 93: 14082-14087.
38. Fisher K et al. Recombinant adeno-associated virus for muscle directed gene therapy. Nature Med 1997; 3: 306-312.
39. Fisher K et al. Transduction with recombinant adeno-associated virus for gene therapy is limited by leading-strand synthesis. J Virol 1996; 70: 520-532.
40. Duan D et al. Circular intermediates of recombinant adeno-associated virus have defined structural characteristics responsible for long-term persistence in muscle tissue. J Virol 1998; 72: 8568-8577.
41. Ni T et al. Cellular proteins required for adeno-associated virus DNA replication in the absence of adenovirus coinfection. J Virol 1998; 72: 2777-2787.
42. Vincent-Lacaze N et al. Structure of adeno-associated virus vector DNA following transduction of the skeletal muscle. J Virol 1999; 73: 1949-1955.
43. Wolberg A, Stafford D, Erie D. Human factor IX binds to specific sites on the collagenous domain of collagen IV. J Biol Chem 1997; 272: 16717-16720.
44. Roberts H, Eberst M, Current management of hemophilia B. Hematol Oncol Clin N Am 1993; 7: 1269-1280.
45. Greelish J et al. Stable restoration of the sarcoglycan complex in dystrophic muscle perfused with histamine and a recombinant adeno-associated viral vector. Nature Med 1999; 5: 439.
46. Ferrari F, Xiao X, McCarty D, Samulski R. New developments in the generation of Ad-free, high-titer rAAV gene therapy vectors. Nature Med 1997; 3: 1295-1297.
47. Hirt B. Selective extraction of polyoma DNA from infected mouse cell cultures. J Mol Biol 1967; 26: 365-369.
48. Sambrook J, Fritsch E, Maniatis T. In: Nolan C (ed). Molecular Cloning - a Laboratory Manual. Cold Spring Harbor Laboratory Press: Cold Spring Harbor, 1989, pp 6.20-21.
49. Kingston R. Analysis of RNA by Northern and slot blot hybridization. In: Ausubel F et al (eds). Current Protocols in Molecular Biology. John Wiley & Sons: 1997, pp 4.9.1-4.9.13.